Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 36
Filtrar
1.
ABCD (São Paulo, Impr.) ; 34(4): e1630, 2021. graf
Artículo en Inglés, Portugués | LILACS | ID: biblio-1360001

RESUMEN

RESUMO - RACIONAL: O estresse oxidativo é um dos principais mecanismos associados à ruptura dos mecanismos de defesa que formam a barreira epitelial cólica e reduz o conteúdo tecidual das proteínas claudina-3 e ocludina principais constituintes das junções de oclusão intercelulares. O sucralfato, possui atividade antioxidante e tem sido usado para tratar diferentes formas de colite. OBJETIVO: Mensurar o conteúdo tecidual de claudina-3 e ocludina da mucosa do cólon sem trânsito fecal, submetido à intervenção com sucralfato. MÉTODO: Trinta e seis ratos foram submetidos à colostomia do cólon esquerdo e fístula mucosa distal. Os animais foram divididos em dois grupos de acordo com a eutanásia ser realizada duas ou quatro semanas após a intervenção. Cada grupo foi dividido em três subgrupos de acordo com o tipo de intervenção realizada diariamente: solução salina isolada; sucralfato a 1 g/kg/dia ou sucralfato a 2g/kg/dia. A colite foi diagnosticada por análise histológica adotando escala de validação prévia. A expressão tecidual de ambas as proteínas foi identificada por imunoistoquímica. O conteúdo das proteínas foi quantificado por análise de imagem assistida por computador. RESULTADOS: O escore inflamatório foi maior nos segmentos cólicos sem trânsito fecal e os enemas com sucralfato reduziram o escore inflamatório nesses segmentos, principalmente nos animais submetidos à intervenção com sucralfato em maior concentração e por período mais longo de intervenção. Houve aumento no conteúdo tecidual das proteínas claudina-3 e ocludina, relacionado com a concentração de sucralfato. O conteúdo tecidual de ambas as proteínas não se modificou com a duração da intervenção. CONCLUSÃO: Enemas com sucralfato reduzem a inflamação e aumentam o conteúdo tecidual de claudina-3 e ocludina na mucosa cólica sem trânsito intestinal.


ABSTRACT - BACKGROUND: Oxidative stress is one of the main mechanisms associated with the rupture of the defense mechanisms of the colonic epithelial barrier; it reduces the tissue content of the claudin-3 and occludin proteins, which are the main constituents of intercellular tight junctions. Sucralfate (SCF) has antioxidant activity and has been used to treat different forms of colitis. AIM: This study aimed to measure the tissue claudin-3 and occludin content of the colon mucosa without fecal transit, subjected to intervention with SCF. METHODS: Thirty-six rats were subjected to left colon colostomy and distal mucous fistula. They were divided into two groups according to euthanasia that was performed 2 or 4 weeks after the intervention. Each group was divided into three subgroups according to the enema applied daily: saline alone, SCF at 1 g/kg/day, or SCF at 2 g/kg/day. Colitis was diagnosed by the histological analysis adopting the previous validate scale. The tissue expression of both proteins was identified by immunohistochemical technique. The content of proteins was quantified by computer-assisted image analysis. RESULTS: The inflammatory score was high in colonic segments without fecal transit, and enemas with SCF reduced the inflammatory score in these segments, mainly in those animals submitted to intervention with SCF in greater concentration and for a longer period of intervention. There was an increase in tissue content of claudin-3 and occludin, related to SCF concentration. The tissue content of both proteins was not related to the intervention time. CONCLUSION: Enemas with SCF reduced the inflammation and increased the tissue content of claudin-3 and occludin in colonic mucosa without fecal stream.


Asunto(s)
Animales , Ratas , Sucralfato/uso terapéutico , Colitis/prevención & control , Colitis/tratamiento farmacológico , Ratas Wistar , Enema
2.
Acta cir. bras ; 29(9): 544-552, 09/2014. graf
Artículo en Inglés | LILACS | ID: lil-722131

RESUMEN

PURPOSE: To evaluate the effects of sucralfate on tissue content of neutral and acids mucins in rats with diversion colitis. METHODS: Thirty-six rats were submitted to a proximal right colostomy and a distal mucous fistula. They were divided into two groups according to sacrifice to be performed two or four weeks after intervention. Each group was divided into three subgroups according daily application of enemas containing saline, sucralfate at 1.0 g/kg/day or 2.0 g/kg/day. Colitis was diagnosed by histological analysis and neutral and acid mucins by Periodic Acid Schiff and Alcian Blue techniques, respectively. The contents of mucins were quantified by computer-assisted image analysis. Student's t paired and ANOVA test were used to compare the contents of both types of mucins among groups, and to verify the variance with time, establishing level of signification of 5% for both (p<0.05). RESULTS: Enemas containing sucralfate improves the inflammation and increases the tissue contents of neutral and acid mucins. The content of neutral mucins does not change with the time or concentration of sucralfate used, while acid mucins increases with concentration and time of intervention. CONCLUSIONS: Sucralfate enemas improve the inflammatory process and increase the tissue content of neutral and acid mucins in colon without fecal stream. .


Asunto(s)
Animales , Masculino , Antiulcerosos/uso terapéutico , Colitis/tratamiento farmacológico , Enema/métodos , Glicoproteínas de Membrana/análisis , Mucinas/análisis , Sucralfato/uso terapéutico , Antiulcerosos/farmacología , Colitis/patología , Colon/efectos de los fármacos , Colon/patología , Modelos Animales de Enfermedad , Procesamiento de Imagen Asistido por Computador , Mucosa Intestinal/efectos de los fármacos , Mucosa Intestinal/patología , Mucinas/efectos de los fármacos , Ratas Wistar , Reproducibilidad de los Resultados , Sucralfato/farmacología , Factores de Tiempo , Resultado del Tratamiento
4.
J. coloproctol. (Rio J., Impr.) ; 33(4): 182-190, Nov-Dec/2013. graf, ilus
Artículo en Inglés | LILACS | ID: lil-697805

RESUMEN

Diversion colitis (DC) is an inflammatory disease that develops in segments with fecal diversion. Sucralfate (SCF) complex, which consists of sucrose octasulfate and polyaluminum hydroxide, has been demonstrated to be effective in the treatment of different forms of colitis. However, until now, the effects of SCF have not been evaluated in DC. OBJECTIVE: to evaluate whether the use of enemas containing SFC improves histological findings in experimental DC. METHODS: Thirty-six rats underwent right colon bypass procedure through the creation of a proximal colostomy and a distal mucous fistula. The animals were divided into two groups according to the euthanization procedure to be performed two to four weeks after surgery. Each experimental group was divided into three subgroups of six animals, which were submitted to daily application of enemas containing saline solution 0.9% or SCF at concentrations of 1.0 g/kg/day or 2.0 g/kg/day, respectively. The diagnosis of DC in segments with fecal diversion was established by histopathological study considering the following variables: epithelial loss, formation of crypt abscesses, the population of goblet cells, inflammatory infiltrate and presence of fibrosis. For statistical analysis, the nonparametric Mann-Whitney and Kruskal-Wallis tests were used, with a significance level of 5% (p <0.05). RESULTS: It was observed that the daily application of SCF enemas decreased epithelial loss, formation of colon crypt abscesses, inflammatory infiltrate and tissue fibrosis (p <0.05), unrelated to time of intervention. The intervention with SCF preserves the goblet cell population. The effects of the substance on the preservation of colonic epithelium; the decrease in the inflammatory process and subsequent abscess formation in the colon crypts are associated with the concentration used, whereas tissue fibrosis decrease is associated with the concentration and time of intervention. CONCLUSION: Preventive application of SCF enemas reduces the inflammatory process in the colon with fecal diversion. (AU)


A colite de exclusão (CE) é uma doença inflamatória que se desenvolve em segmentos desprovidos de trânsito fecal. O sucralfato (SCF) complexo formado pelo octossulfato de sacarose e hidróxido de polialumínio vem se demonstrando eficaz para o tratamento de diferentes formas de colite, porém, até a presente data, os efeitos do SCF ainda não foram avaliados na CE. OBJETIVO: avaliar se a aplicação de clisteres contendo SFC melhora as alterações histológicas encontradas em modelo experimental de CE. MÉTODOS: trinta e seis ratos foram submetidos à derivação do trânsito no cólon direito pela confecção de colostomia proximal e fístula mucosa distal. Os animais foram divididos em dois grupos experimentais de acordo com o sacrifício ser realizado após duas ou quatro semanas do procedimento cirúrgico. Cada grupo experimental foi dividido em três subgrupos de seis animais segundo terem sidos submetidos à aplicação diária com enemas contendo solução fisiológica a 0,9% ou SCF nas concentrações de 1,0g/kg/dia ou 2,0 g/kg/dia. O diagnóstico de CE nos segmentos sem trânsito foi estabelecido por estudo histopatológico considerando-se as seguintes variáveis: perda epitelial, formação de abscessos nas criptas, população de células caliciformes, infiltrado inflamatório e a presença de fibrose. Para análise estatística adotou-se os testes não paramétricos de Mann-Withney e Kruskal-Wallis estabelecendo-se para ambos, nível de significância de 5% (p < 0,05). RESULTADOS: verificou-se que a aplicação diária de enemas com SCF diminui a perda epitelial, a formação de abscessos nas criptas cólicas, o infiltrado inflamatório e a presença de fibrose tecidual (p < 0,05), não relacionada ao tempo de intervenção. A intervenção com SCF preserva a população de células caliciformes. Os efeitos da substância na preservação do epitélio cólico, na redução do processo inflamatório e consequente formação de abscessos nas criptas cólicas encontram-se relacionado à concentração utilizada, enquanto a redução da fibrose tecidual a concentração e ao tempo de intervenção. CONCLUSÃO: a aplicação preventiva de enemas com SCF reduz o processo inflamatório em segmentos cólicos desprovidos de transito intestinal. (AU)


Asunto(s)
Animales , Ratas , Sucralfato/uso terapéutico , Colitis/terapia , Colon/patología , Enema , Epitelio/lesiones
5.
Gut and Liver ; : 752-755, 2013.
Artículo en Inglés | WPRIM | ID: wpr-209548

RESUMEN

Solitary rectal ulcer syndrome (SRUS) is a rare, benign disorder in children that usually presents with rectal bleeding, constipation, mucous discharge, prolonged straining, tenesmus, lower abdominal pain, and localized pain in the perineal area. The underlying etiology is not well understood, but it is secondary to ischemic changes and trauma in the rectum associated with paradoxical contraction of the pelvic floor and the external anal sphincter muscles; rectal prolapse has also been implicated in the pathogenesis. This syndrome is diagnosed based on clinical symptoms and endoscopic and histological findings, but SRUS often goes unrecognized or is easily confused with other diseases such as inflammatory bowel disease, amoebiasis, malignancy, and other causes of rectal bleeding such as a juvenile polyps. SRUS should be suspected in patients experiencing rectal discharge of blood and mucus in addition to previous disorders of evacuation. We herein report six pediatric cases with SRUS.


Asunto(s)
Adolescente , Niño , Femenino , Humanos , Masculino , Antiinflamatorios no Esteroideos/uso terapéutico , Antiulcerosos/uso terapéutico , Colonoscopía , Hemorragia Gastrointestinal/diagnóstico , Mesalamina/uso terapéutico , Enfermedades del Recto/diagnóstico , Esteroides/uso terapéutico , Sucralfato/uso terapéutico , Síndrome , Úlcera/diagnóstico
6.
Indian J Exp Biol ; 2006 Apr; 44(4): 292-9
Artículo en Inglés | IMSEAR | ID: sea-62015

RESUMEN

Methanolic extract of Musa sapientum var. Paradisiaca (MSE, 100 mg/kg) was studied for its antiulcer and mucosal defensive factors in normal and non-insulin dependent diabetes mellitus (NIDDM) rats. NIDDM was induced by administering streptozotocin (STZ, 70 mg/kg, ip) to 5 days old rat pups. The animals showing blood glucose level >140mg/dL after 12 weeks of STZ administration were considered as NIDDM positive. Effects of MSE were compared with known ulcer protective drug, sucralfate (SFT, 500 mg/kg) and anti-diabetic drug glibenclamide (GLC, 0.6 mg/kg) when administered orally, once daily for 6 days against gastric ulcers (GU) induced by cold-restraint stress (CRS) and ethanol and subsequent changes in gastric mucosal glycoproteins, cell proliferation, free radicals (lipid peroxidation and nitric oxide) and anti-oxidants enzymes (super oxide dismutase and catalase) and glutathione (GSH) levels. MSE showed better ulcer protective effect in NIDDM rats compared with SFT and GLC in CRS-induced GU. NIDDM caused a significant decrease in gastric mucosal glycoprotein level without having any effect on cell proliferation. However, all the test drugs reversed the decrease in glycoprotein level in NIDDM rats, but cell proliferation was enhanced in case of MSE alone. Both CRS or NIDDM as such enhanced gastric mucosal LPO, NO and SOD, but decreased CAT levels while CRS plus NIDDM rats caused further increase in LPO and NO level without causing any further changes in SOD and CAT level. MSE pretreatment showed reversal in the levels of all the above parameters better than GLC. Ethanol caused a decrease in glutathione level which was further reduced in NIDDM-ethanol rats. MSE reversed the above changes significantly in both normal as well as in NIDDM rats, while GLC reversed it only in NIDDM rats. However, SFT was ineffective in reversing the changes induced by CRS or ethanol or when given in NIDDM-CRS or NIDDM-ethanol rats. The results indicated that the ulcer protective effect of MSE could be due to its predominant effect on mucosal glycoprotein, cell proliferation, free radicals and antioxidant systems.


Asunto(s)
Animales , Antioxidantes/metabolismo , Proliferación Celular , Diabetes Mellitus Tipo 2 , Femenino , Radicales Libres/metabolismo , Glutatión/metabolismo , Glicoproteínas/metabolismo , Masculino , Musa/química , Extractos Vegetales/química , Ratas , Úlcera Gástrica/inducido químicamente , Estreptozocina/farmacología , Sucralfato/uso terapéutico
7.
Artículo en Inglés | IMSEAR | ID: sea-124851

RESUMEN

The objective of the study was to assess the efficacy of the H2-receptor antagonists and sucralfate for the prophylaxis of stress ulcer in patients on a ventilator in an intensive care unit in the general intensive care unit of our institute. A randomized, clinical controlled trial was conducted. Fifty-two critically ill patients, who required mechanical ventilation for more than 24 hours, were randomly divided into 3 groups. Group I received ranitidine 50 mg (intravenous) 8 hourly, group II received tablet sucralfate 1 g 8 hourly through a Ryle's tube, whereas group III was not given any drug. The incidence of upper gastrointestinal bleed, change in gastric pH and growth of gram-negative organisms in the gastric juice and bronchoalveolar lavage (BAL) culture were noted and analysed. The treatment groups were similar with respect to the baseline characteristics. The incidence of upper gastrointestinal bleeding was similar in the ranitidine (12.5%) and sucralfate groups (14.35%) but was high in the control group (57.14%). The mean gastric pH was significantly low in the control group (mean pH 2.07) compared to the ranitidine (mean pH 5.25) and sucralfate groups(mean pH 3.54)(p < 0.05). The incidence of positive culture for gram-negative organisms was significantly high in the ranitidine group (75%) in comparison with the sucralfate group (33.33%) (p < 0.002). However, the incidence of positive growth in the BAL culture was similar in all three groups. We conclude that both ranitidine and sucralfate are equally effective in decreasing the incidence of upper gastrointestinal haemorrhage and other stress- related lesions. Though ranitidine was more effective in increasing the gastric pH, the incidence of gastric colonization was higher in the ranitidine group compared to the sucralfate group.


Asunto(s)
Adulto , Antiulcerosos/uso terapéutico , Infecciones Bacterianas/etiología , Método Doble Ciego , Femenino , Humanos , Modelos Logísticos , Masculino , Úlcera Péptica/microbiología , Úlcera Péptica Hemorrágica/prevención & control , Estudios Prospectivos , Ranitidina/uso terapéutico , Respiración Artificial , Estadísticas no Paramétricas , Estrés Psicológico , Sucralfato/uso terapéutico
8.
Indian J Physiol Pharmacol ; 2000 Oct; 44(4): 435-41
Artículo en Inglés | IMSEAR | ID: sea-106759

RESUMEN

The anti-ulcerogenic effect of fresh juice from the whole plant of Bocapa monniera Wettst. (BMJ) commonly known as Brahmi in Hindi was examined using gastric ulcer models induced by ethanol, aspirin, 2 h cold restraint stress and 4 h pylorus ligation. Bocapa monniera juice (BMJ) at doses of 100 and 300 mg/kg and sucralfate at a dose of 250 mg/kg were given orally, twice daily for 5 days. BMJ 100-300 mg/kg produced significant antiulcer activity in all the experimental gastric ulcer models except in case of ethanol-induced ulcers where 100 mg/kg was not found to decrease it significantly. BMJ (100-300 mg/kg) was found to have little or no effect on the offensive acid-pepsin secretion, while cell shedding (microgram DNA/mg of protein) and mucin secretion in terms of total carbohydrates:protein ration (TC:P), the two important parameters of defensive factors were significantly decreased and increased respectively indicating enhancement of protective mucosal factors. Both BMJ (300 mg/kg) and SF showed tendency to increase the mucosal glycoproteins in terms of TC:P, though individual carbohydrates and total carbohydrates were either increased or showed a tendency to increase. Thus, ulcer protective effect of BMJ may be due to its effect on mucosal defensive factors like enhanced mucin secretion, mucosal glycoprotein and decreased cell shedding rather than on offensive factors such as acid and pepsin.


Asunto(s)
Animales , Antiulcerosos/uso terapéutico , Aspirina , Depresores del Sistema Nervioso Central , Frío , ADN/metabolismo , Úlcera Duodenal/tratamiento farmacológico , Etanol , Femenino , Ácido Gástrico/metabolismo , Jugo Gástrico/metabolismo , Masculino , Pepsina A/metabolismo , Fitoterapia , Extractos Vegetales/uso terapéutico , Plantas Medicinales/uso terapéutico , Ratas , Úlcera Gástrica/tratamiento farmacológico , Estrés Fisiológico , Sucralfato/uso terapéutico
10.
Rev. gastroenterol. Méx ; 63(2): 101-5, abr.-jun. 1998. tab, ilus
Artículo en Español | LILACS | ID: lil-240899

RESUMEN

Las tetraciclinas están descritas como antibióticos que suelen producir úlceras esofágicas. Objetivo. Ver el comportamiento de este tipo de úlceras, así como la respuesta al manejo con sucralfato. Método. Es un estudio retrospectivo de los últimos dos años donde se revisaron los casos de odinofagia y disfagia sometidos a endoscopia con antecedentes de ingesta reciente de doxiciclina. Todos fueron tratados suspendiendo la droga, mientras la gran mayoría recibieron tratamiento adicional con sucralfato 1 g cada ocho horas. Resultados. Once pacientes tuvieron como indicación: enfermedad pélvica inflamatoria, acné, infecciones urinarias y respiratorias. El síntoma más común fue odinofagia, presentándose aproximadamente 6 días después de iniciado el tratamiento con varios factores contribuyentes bien comprobados como ingesta antes de acostarse y con poco líquido. Las úlceras se caracterizaron por ser múltiples y localizadas principalmente en el tercio medio. La sintomatología en general cedió 3.7 días después de suspender los medicamentos, mientras aquellos con sucrafalto no mostraron menor duración de los síntomas. Conclusiones. Debemos ser conscientes de la inducción de úlceras por estos medicamentos, basando su tratamiento en la suspensión del antibiótico, recordando que el sucralfato puede ser parte del tratamiento ya que ha demostrado su adherencia a úlceras y lesiones esofágicas, aunque su uso no ha demostrado significancia clínica. Por ende debemos explicar las medidas prevención, como tomarlas con suficiente volumen de agua, en posición, como tomarlas con suficiente volumen de agua, en posición supina y tener precaución especial en ancianos y pacientes con patología anatómica y/o de motilidad esofágica


Asunto(s)
Humanos , Masculino , Femenino , Adolescente , Adulto , Antiulcerosos/uso terapéutico , Antibacterianos/efectos adversos , Doxiciclina/efectos adversos , Enfermedades del Esófago/inducido químicamente , Enfermedades del Esófago/diagnóstico , Enfermedades del Esófago/tratamiento farmacológico , Esofagoscopía , Factores de Riesgo , Sucralfato/uso terapéutico , Tetraciclina/efectos adversos , Úlcera/diagnóstico , Úlcera/inducido químicamente , Úlcera/tratamiento farmacológico
11.
Rev. gastroenterol. Méx ; 63(2): 106-7, abr.-jun. 1998. ilus
Artículo en Español | LILACS | ID: lil-240900

RESUMEN

Una mujer de 25 años de edad se presentó con odinofagia y dolor retroesternal de aparición súbita. Había ingerido metronidazol 500 mg cada 8 horas durante 3 días previos y la última tableta fue ingerida la noche anterior sin líquido antes de dormir. La esofagoscopía demostró dos úlceras circunferenciales en el tercio medio del esófago. El tratamiento consistió en suspender el metronidazol, tomar sucralfato pulverizado 2 g cada 12 horas y dieta líquida con curación clínica y endoscópica a los 7 días. Consideramos importante informar este caso dada la administración frecuente de este medicamento en México


Asunto(s)
Humanos , Femenino , Adulto , Antiulcerosos/efectos adversos , Antiulcerosos/uso terapéutico , Enfermedades del Esófago/inducido químicamente , Enfermedades del Esófago/diagnóstico , Esofagoscopía , Metronidazol/efectos adversos , Sucralfato/uso terapéutico , Úlcera/diagnóstico , Úlcera/inducido químicamente , Úlcera/tratamiento farmacológico
12.
Artículo en Inglés | IMSEAR | ID: sea-40238

RESUMEN

A comparative study using antacid and sucralfate suspension in the treatment of upper G.I. hemorrhage showed that bleeding stigmenta occurred less in the sucralfate group than in the antacid group in a statistically significant number. Sucralfate therefore is an alterative preferable choice in the treatment of UGH.


Asunto(s)
Enfermedad Aguda , Administración Oral , Adulto , Antiácidos/uso terapéutico , Método Doble Ciego , Femenino , Fármacos Gastrointestinales/uso terapéutico , Hemorragia Gastrointestinal/tratamiento farmacológico , Gastroscopía , Humanos , Incidencia , Masculino , Persona de Mediana Edad , Estudios Retrospectivos , Sucralfato/uso terapéutico , Suspensiones , Tailandia/epidemiología , Resultado del Tratamiento
13.
Artículo en Inglés | IMSEAR | ID: sea-63549

RESUMEN

BACKGROUND: Colloidal bismuth subcitrate (CBS) causes endoscopic and histological improvement in gastritis and eradication of Helicobacter pylori in patients with non-ulcer dyspepsia (NUD). The effect of sucralfate, a cytoprotective drug, on endoscopic and histologic gastritis and H pylori clearance is not clear. We studied the effect of CBS and sucralfate on these features in patients with NUD. METHODS: Sixty three patients with NUD and H pylori infection were randomized to receive one of the following for four weeks: (i) CBS (240 mg twice daily) (Group 1); (ii) placebo I, similar in size, color and shape to CBS (Group 2); (iii) sucralfate (2.0 g twice daily) (Group 3) and (iv) placebo II, similar to sucralfate (Group 4). Symptoms, endoscopic and histological findings and H pylori status were assessed before and after treatment. RESULTS: Similar symptomatic improvement was observed with each treatment, indicating a placebo effect. Significant endoscopic and histological improvement was observed with CBS only. CBS was better than sucralfate in inducing endoscopic and histological improvement. Clearance rate of H pylori was 46.6% with CBS, 16.6% with its placebo, 33.3% with sucralfate and 13.3% with its placebo. CONCLUSION: CBS is more effective than sucralfate in inducing endoscopic and histologic healing of H pylori-related gastritis among NUD patients.


Asunto(s)
Adulto , Antibacterianos/uso terapéutico , Antiulcerosos/uso terapéutico , Dispepsia/tratamiento farmacológico , Femenino , Gastritis/tratamiento farmacológico , Infecciones por Helicobacter/tratamiento farmacológico , Helicobacter pylori , Humanos , Masculino , Compuestos Organometálicos/uso terapéutico , Sucralfato/uso terapéutico
14.
Artículo en Inglés | IMSEAR | ID: sea-64498

RESUMEN

BACKGROUND: Sucralfate is known to protect gastroduodenal mucosa and thereby facilitate healing of peptic ulcer. The mechanism of action of this drug is still not fully known. METHODS: We studied the effect of sucralfate treatment on gastric bicarbonate secretion in 16 patients with duodenal ulcer. RESULTS: Sucralfate administration (3 g daily for 4 weeks) stimulated bicarbonate secretion from 3.1 +/- 1.2 mmol/h to 4.6 +/- 2.0 mmol/h (p < 0.05). Gastric juice volume as well as non-parietal volume secretion also increased significantly after sucralfate therapy (p < 0.05). CONCLUSION: Sucralfate causes stimulation of non-parietal volume-dependent gastric bicarbonate secretion.


Asunto(s)
Adulto , Bicarbonatos/metabolismo , Esquema de Medicación , Úlcera Duodenal/tratamiento farmacológico , Jugo Gástrico/metabolismo , Mucosa Gástrica/efectos de los fármacos , Humanos , Persona de Mediana Edad , Estimulación Química , Sucralfato/uso terapéutico
16.
Acta gastroenterol. latinoam ; 25(3): 145-52, 1995. tab, ilus
Artículo en Español | LILACS | ID: lil-159744

RESUMEN

Se estudiaron en grupos de ratas Wistar, en stress por inmovilización más inmersión en agua a 18C, las groseras lesiones agudas gástricas sangrantes y su prevención con drogas citoprotectoras gástricas como: sucralfato, HOAI y Mg, magaldrato, hidrotalcita y misoprostol; asimismo, drogas antisecretoras gástricas como misoprostol (dosis antisecretora), somatostatina (octeotride), ranitidina, omeprazol y lanzoprazol. En otra experiencia, se estudió la secreción gástrica ácida en ratas con ligadura de píloro, donde fueron tratadas con las mismas drogas y dosis que en la experiencia anterior. Se comprobó que el modelo de stress 6 hs. dió una zona lesional gástrica de un 80 por ciento; el sucralfato, como droga citoprotectora, dio una protección parcial de la mucosa gástrica; en cambio, los bloqueantes de la bomba de protones, omeprazol y lanzoprazol dieron una zona gástrica cercana al 0 por ciento y por ende, postulamos su uso en terapia intensiva en la profilaxis de las lesiones agudas gástricas sangrantes en el stress.


Asunto(s)
Animales , Ratas , Femenino , Gastritis/prevención & control , Mucosa Gástrica/patología , Úlcera Gástrica/prevención & control , Ácido Gástrico , Hidróxido de Aluminio/administración & dosificación , Hidróxido de Aluminio/uso terapéutico , Hidróxido de Magnesio/administración & dosificación , Hidróxido de Magnesio/uso terapéutico , Misoprostol/administración & dosificación , Misoprostol/uso terapéutico , Omeprazol/administración & dosificación , Omeprazol/uso terapéutico , Ranitidina/administración & dosificación , Ranitidina/uso terapéutico , Somatostatina/administración & dosificación , Somatostatina/uso terapéutico , Estrés Fisiológico , Sucralfato/administración & dosificación , Sucralfato/uso terapéutico
17.
Artículo en Inglés | IMSEAR | ID: sea-38947

RESUMEN

104 duodenal ulcer patients were classified into non-smokers (76) and smokers (28). Their age range was between 14-72 years. They were randomly treated with cimetidine (28 non-smokers and 8 smokers), colloidal bismuth (27 non-smokers and 10 smokers) and sucralfate (21 non-smokers and 10 smokers). Follow-up endoscopic examination at 4, 6 and 8 weeks showed that overall healing rates were better in the non-smokers than in the smokers (64.5% against 46.4% at 4 weeks and 92.1% against 67.8% at 6 weeks) and almost all ulcers had healed at the end of 8 weeks (100% in non-smokers and 96.4% in smokers). Among non-smokers, there were no statistically significant differences in the healing rates by any medication at any period of time. Among smokers, colloidal bismuth had significant better healing rate at 6 weeks over cimetidine and sucralfate. (p = 0.04 and p = 0.041 respectively). Overall relapse rates were higher among smokers (32.1%) than non-smokers (10.5%). Of the 3 medications, sucralfate had the lowest relapse rate in both smokers (20%) and non-smokers (9.5%), while colloidal bismuth had the highest relapse rates (40% for smokers and 11.1% for non-smokers).


Asunto(s)
Adolescente , Adulto , Anciano , Bismuto/uso terapéutico , Cimetidina/uso terapéutico , Coloides , Úlcera Duodenal/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Recurrencia , Fumar , Sucralfato/uso terapéutico , Resultado del Tratamiento
19.
Artículo en Inglés | IMSEAR | ID: sea-88640

RESUMEN

A total of 40 patients with endoscopically proved reflux esophagitis were treated in a randomised study. Treatment was given for six weeks and consisted of daily doses of either 1 gm sucralfate four times a day or one, 150 mg ranitidine tablet twice daily. Twenty patients received each drug. Clinical evaluation was done weekly and endoscopic evaluation after six weeks. Forty percent patients on ranitidine and 50% patients on sucralfate became asymptomatic at six weeks. Fifty percent patients on ranitidine and 60% patients on sucralfate were endoscopically healed. The results did not show any difference in the effect of ranitidine and sucralfate treatment (p > 0.05). Overall tolerance and compliance in the two forms of treatment was good. Though ranitidine has a more convenient dose schedule and is more cost effective, sucralfate needs further clinical trials.


Asunto(s)
Adulto , Anciano , Esofagitis Péptica/tratamiento farmacológico , Femenino , Humanos , Masculino , Persona de Mediana Edad , Cooperación del Paciente , Ranitidina/uso terapéutico , Sucralfato/uso terapéutico
20.
Bangladesh Med Res Counc Bull ; 1992 Apr; 18(1): 23-9
Artículo en Inglés | IMSEAR | ID: sea-469

RESUMEN

Sixty subjects were carefully interrogated and repeatedly endoscoped with a view to studying the effect of sucralfate on healing and recurrence of duodenal ulcer disease. Degree of bulbar deformity was noted during each endoscopy. During the trial it appeared that deformity progressed more rapidly in late onset subjects (onset at or above 30 years of age). In eight subjects deformity became gross over a period of three years. Seven of them belonged to the late onset subgroup. Two subject had large ulcers and both belonged to the late onset subgroup, one had rapidly progressive disease. Out of six subjects with multiple ulcers four belonged to the late onset subgroup, two of the later had rapidly progressive disease.


Asunto(s)
Adulto , Úlcera Duodenal/tratamiento farmacológico , Duodenoscopía , Duodeno/patología , Femenino , Humanos , Masculino , Sucralfato/uso terapéutico
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA